The Genetic Basis of Delayed Puberty

Sasha R. Howard · Leo Dunkel

Centre for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

Keywords

Pubertal timing · Self-limited delayed puberty · Constitutional delay · Genetics · Adolescent development

Abstract

The genetic control of puberty remains an important but mostly unanswered question. Late pubertal timing affects over 2% of adolescents and is associated with adverse health outcomes including short stature, reduced bone mineral density, and compromised psychosocial health. Self-limited delayed puberty (DP) is a highly heritable trait, which often segregates in an autosomal dominant pattern; however, its neuroendocrine pathophysiology and genetic regulation remain unclear. Some insights into the genetic mutations that lead to familial DP have come from sequencing genes known to cause gonadotropin-releasing hormone (GnRH) deficiency, most recently via next-generation sequencing, and others from large-scale genome-wide association studies in the general population. Investigation of the genetic control of DP is complicated by the fact that this trait is not rare and that the phenotype is likely to represent a final common pathway, with a variety of different pathogenic mechanisms affecting the release of the puberty “brake.” These include abnormalities of GnRH neuronal development and function, GnRH receptor and luteinizing hormone/follicle-

stimulating hormone abnormalities, metabolic and energy homeostatic derangements, and transcriptional regulation of the hypothalamic-pituitary-gonadal axis. Thus, genetic control of pubertal timing can range from early fetal life via development of the GnRH network to those factors directly influencing the puberty brake during mid-childhood.

© 2017 S. Karger AG, Basel

Introduction

Puberty is the maturational process of the reproductive endocrine system that results in achievement of adult height and body proportion, in addition to development of the genital organs and the capacity to reproduce. The onset of puberty is driven by an increase in the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This activation results in increased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the anterior pituitary; both hormones act on the gonads to stimulate their development, gametogenesis, and sex steroid production.

The development of the hypothalamic-pituitary-gonadal (HPG) axis is exceptional in that GnRH neurons develop in metazoan embryos outside of the central ner-

Fig. 1. The genetics of pubertal timing. In the general population there is a near-normal distribution of the timing of pubertal onset, with the definitions of precocious and delayed being statistically determined (± 2 standard deviations [SD]). Strategies to determine key genetic determinants in the timing of puberty include large genome-wide association studies (GWAS) of age at menarche and voice breaking in the general population, and identification of rare high-impact variants causing early, late, or absent puberty in patients and their families. G2, Tanner genital stage 2 in boys; yr, years.

vous system. Immature GnRH precursor neurons are first detectable in the olfactory placode in the nose from an early embryological stage, and then begin a complex journey towards the hypothalamus [1].

The axis is active in fetal and in early infant life, the so-called “mini-puberty,” and then becomes dormant between the age of 1 and 8–9 years [2]. Development of the clinical features of puberty is initiated by the reactivation of the HPG axis after this relative quiescence during childhood. What drives this suppression of the axis during childhood, and what controls the release of this “brake” and the timing at which this occurs, is little understood.

Despite the demonstrated importance of environmental factors such as body mass, psychosocial stressors, and endocrine disrupting chemicals [3], the genetic influence on the timing of puberty is clearly fundamental. Whilst the timing of pubertal onset varies within and between different populations, it is a highly heritable trait. The timing of sexual maturation is highly correlated within families and in twin studies, suggesting strong genetic determinants [4]. Previous epidemiological studies and genetic approaches estimate that 60–80% of the variation in pubertal onset is under genetic regulation [5, 6]. However, despite this strong heritability, little is known about the genetic control of human puberty, either in the normal population or in cases of disturbed pubertal timing [7].

Investigating the Inheritance of Delayed Puberty

Self-limited delayed puberty (DP), also known as constitutional delay of growth and puberty, represents the extreme end of normal pubertal timing, and is defined as the absence of testicular enlargement in boys or breast development in girls at an age that is 2 to 2.5 standard deviations later than the population mean [7]. In addition, cases of self-limited DP may also encompass older children with delayed pubertal progression, a diagnosis that is aided by the use of puberty nomograms [8]. Self-limited DP is associated with adverse health outcomes including short stature, reduced bone mineral density, and compromised psychosocial health [9].

Self-limited DP represents the commonest cause of DP in both sexes. Up to 63% of boys with pubertal delay have self-limited DP [10]. Self-limited DP segregates within families with complex patterns of inheritance including autosomal dominant, autosomal recessive, bilineal, and X-linked [11], although sporadic cases are also observed (Fig. 1). The majority of families display an autosomal dominant pattern of inheritance (with or without complete penetrance) [4, 11]. Fifty to 75% of subjects with self-limited DP have a family history of delayed pubertal onset [11].

Analysis of self-limited DP families is complicated by the fact that this phenotype represents the tail of a normally distributed trait within the population, so it is ex-

pected that variants that govern the inheritance of this condition will also be present in the general population at a low level. Thus, the absence of these variants in population databases cannot be used as an exclusion criterion. Instead, a comparison of prevalence rates of such variants must be made to identify those that are enriched in patients compared to the general population. In the majority of patients with DP the neuroendocrine pathophysiology and its genetic regulation remain unclear. Linkage analysis and targeted sequencing strategies appear to have been superseded by whole exome and genome sequencing strategies to identify novel candidate genes.

Evidence from Population Studies

Attempts to identify key genetic regulators of the timing of puberty in humans have led to several large genome-wide association studies of age at menarche, examining pubertal timing in healthy women [12–14]. These studies demonstrate genetic heterogeneity in pubertal timing, with the observation that the genetic architecture of the timing of puberty in healthy subjects is likely to involve at least hundreds of common variants. The first of many loci associated with age at menarche was the gene *LIN28B* [15]. *LIN28B* is a human orthologue of the gene that controls, through microRNAs, developmental timing in *Caenorhabditis elegans*. However, mutations in *LIN28B* have not to date been identified in human patients with DP [16] or precocious puberty [17].

The most recent study of this type comprises 1000 Genomes Project-imputed genotype data from up to ~370,000 women, and identifies 389 independent signals ($p < 5 \times 10^{-8}$) for age at menarche [18]. The per-allele effect sizes ranged from 1 week to 5 months. These signals explain ~7.4% of the population variance in age at menarche, corresponding to ~25% of the estimated heritability. Many of these signals have concordant effects on the age at voice breaking, a corresponding milestone in males. However, in women the signals identified had stronger effects on early than on late age at menarche, but in contrast had larger effect estimates for relatively late than relatively early voice breaking in males [18].

Around 250 genes were identified via coding variation or associated expression, particularly those expressed in neural tissues. Importantly, genes already implicated in rare disorders of puberty were identified, including *LEPR*, *GNRH1*, *KISS1*, and *TACR3*. Two imprinted genes were also reported: *MKRN3*, paternally inherited mutations in which have been identified as causal in pedigrees of

central precocious puberty (CPP) [19], and *DLK1* [20]. *MKRN3* is the third, and to date the most frequently mutated, gene in pedigrees with CPP [19], the others being *KISS1* [21] and its receptor *GPR54* [22], which have been reported only rarely. *MKRN3* is thought to contribute to the puberty “brake” restraining the HPG axis via inhibition of GnRH release. Very recently a complex defect in *DLK1* has been identified in one pedigree with CPP [20]. However, neither *MKRN3* nor *DLK1* mutations have been implicated in the pathogenesis of DP (Fig. 2).

Genetics of GnRH Deficiency or Signalling

At the extreme end of the spectrum of DP are conditions of GnRH deficiency including hypogonadotropic hypogonadism (HH), with complete failure to enter puberty. The condition may be due to failure of development of GnRH neurons, lack of activation of GnRH secretion, or disrupted GnRH signalling. Because of different causes and incomplete penetrance, there is a wide spectrum of phenotypes, ranging from complete HH with lack of pubertal development to a partial hypogonadism with an arrest of pubertal development, and even reversible HH in some patients after treatment [23, 24]. Despite recent advances, with over 20 genes linked to this disorder identified, the pathophysiological basis of HH in approximately 50% of individuals remains unclear [2]. In view of the possible overlap between the pathophysiology of DP and conditions of GnRH deficiency, a few studies have examined the contribution of mutations in HH genes to the phenotype of self-limited DP.

Loss-of-function mutations within the GnRH receptor are the most frequent cause of autosomal recessive idiopathic HH, accounting for 16–40% of patients. Mutations have been found within the extracellular, transmembrane, and intracellular domains of the receptor, leading to impaired GnRH action [25]. A homozygous partial loss-of-function mutation in *GNRHR* was found in 2 brothers, 1 with self-limited DP and 1 with idiopathic HH [26], and a further heterozygous mutation was found in 1 male with self-limited DP [27]. A small cohort of 31 patients was analysed for mutations in *GHSR*, and 5 patients were found to have point mutations in this gene [28]. Additionally, mutations in *HS6ST1*, *FGFR1*, and newly in *KLB* have been found in a small number of kindreds of HH patients and their relatives with DP [29–31]. Recently, variants in several HH genes including *GNRHR*, *TAC3*, *TACR3*, *IL17RD*, and *SEMA3A* have been identified by whole exome sequencing in some cases of DP, including

Fig. 2. Overlap between genetic regulation in the general population and extreme phenotypes. Examples of genes implicated in the timing of puberty from genome-wide association studies (GWAS) in the general population, conditions of gonadotropin-releasing hormone (GnRH) deficiency such as idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS), and self-limited delayed puberty.

self-limited DP [32]. However, these variants have not been tested in vitro or in vivo for pathogenicity and thus may be an overestimation. However, the current picture indicates that the genetic background of HH and DP may be largely different, or shared by as yet undiscovered genes [27].

Genetic defects affecting the development of the anterior pituitary may also cause GnRH deficiency. The pituitary transcription factors *LHX3*, *SOX2*, and *HESX1* are vital for early patterning of the forebrain and pituitary, and mutations in these developmental genes result in syndromic hypopituitarism with gonadotropin deficiency in humans [33]. *PRO1* is important for the development of gonadotropin-secreting cells, and mutations in this gene are the most common cause of combined pituitary hormone deficiency in humans [34]. Patients with *PRO1* mutations have variable GnRH deficiency ranging from DP to congenital HH [33]. Mutations in *DAX1* cause X-linked adrenal hypoplasia congenita with associated HH, but have not been found in cases of isolated DP [35].

GnRH deficiency may also be associated with other conditions, particularly with neurological phenotypes. Mutations in *POLR3A/B* result in the 4H syndrome (hypomyelination, hypodontia, and hypogonadotropic hypogonadism) [36], whilst those in *RNF216*, *OTUD4*, and *PNPLA6* produce the phenotypic combination of HH and ataxia (also known as Gordon Holmes syndrome) [37, 38]. *DMXL2* mutations are associated with

congenital HH, other endocrine deficiencies, and polyneuropathies [39]. Dysregulation of the RAB3 cycle, such as with mutations in *RAB3GAP1*, leads to Warburg Micro syndrome with ocular, neurodevelopmental, and central reproductive defects [40, 41].

Downstream mutations in the GnRH signalling pathway can also present as DP. LH and FSH are glycoprotein hormones encoded by a common α -subunit gene and a specific β -subunit gene. Mutations of the β -subunit genes of LH or FSH are extremely rare causes of pubertal abnormalities [42]. Males with inactivating mutations of the *LHB* have absent pubertal development with Leydig cell hypoplasia leading to T deficiency and azoospermia. Females with inactivating mutations of *LHB* present with onset of normal puberty, but with normal or late menarche followed by infertility due to lack of ovulation [42]. Individuals with inactivating *FSHB* mutations present with incomplete pubertal development and azoospermia if they are male, and with primary amenorrhoea if they are female [43].

Upstream Regulation of the HPG Axis

Kisspeptin, an excitatory neuropeptide, was identified as a permissive factor in puberty onset by the discovery of patients with GnRH deficiency with loss-of-function mutations in the *KISS1* receptor, *KISS1R* (previously known as *GPR54*) [44, 45]. Mice with knockout of *Kiss1r* were

simultaneously discovered to be infertile despite anatomically normal GnRH neurons and normal hypothalamic GnRH levels [45], with a phenotype consistent with normosmic GnRH deficiency. However, to date, only very rarely have human mutations in *KISS1* been found in patients with delayed or absent puberty [46].

The excitatory neuropeptide neurokinin B also plays a role in the upstream control of GnRH secretion. Identification of this pathway occurred also via discovery of loss-of-function mutations in *TAC3*, encoding neurokinin B, and its receptor *TACR3* in patients with normosmic GnRH deficiency and pubertal failure [47]. Kisspeptin, neurokinin B, and dynorphin are coexpressed in KNDy neurons of the arcuate nucleus of the hypothalamus [48], which project to and directly interact with GnRH neurons. Their expression is downregulated by oestrogen and testosterone as part of the negative feedback regulation of gonadotropin secretion [49, 50]. However, administration of neurokinin B agonists failed to stimulate GnRH release in rodents, and *Tacr3* knockout mice have grossly normal fertility [51, 52]. Among 50 self-limited DP patients investigated for mutations in *TAC3* and *TACR3*, only 1 mutation in a single patient was found in the latter gene [53].

The inhibitory role of GABAergic neurotransmission has been clearly shown in primates [54] but is more ambiguous in rodents. Opioid peptides provide additional inhibitory input, but this appears to be less critical than the GABAergic signals in restraining the initiation of puberty [55]. Additionally, RFamide-related peptide gene (*RFRP*), the mammalian orthologue of the avian peptide gonadotropin-inhibiting hormone (*GnIH*), has been identified as a further inhibitory regulator of GnRH neuronal activity in mice [56]. Glial inputs appear to be predominantly facilitatory during puberty and consist of growth factors and small diffusible molecules, including TGF- β ₁, IGF-1, and neuregulins, that directly or indirectly stimulate GnRH secretion [57].

Upstream regulation of GnRH transcription is less well established. Candidate transcriptional regulators identified from a systems biology approach and animal models include *Oct-2*, *TTF-1*, and *EAP1* [58]. *Oct-2* mRNA is upregulated in the hypothalamus in juvenile rodents, and blockage of Oct-2 synthesis delays the age at first ovulation, whilst activation of Oct-2 expression (e.g., hamartomas) induces precocious puberty [59]. *TTF-1* (thyroid transcription factor 1) enhances GnRH expression, with increased expression in pubertal rhesus monkeys [60]. *EAP1* mRNA levels also increase in the hypothalamus of primates and rodents during puberty. *EAP1*

transactivates the *GnRH* promoter, and *EAP1* knock-down with siRNA caused DP and disrupted oestrous cyclicity in a rodent model [61]. However, to date no mutations in these upstream or regulatory factors have been reported in patients with DP.

Epigenetic regulators are potential mediators of the effects of the environment on the hypothalamic regulation of puberty. However, whilst experimental data from rats give evidence for changes in histone acetylation and gene methylation leading to altered gene expression during puberty, the link between environmental factors and epigenetic control of puberty via the hypothalamus has not been established. Recent evidence highlights the importance in mice of microRNAs (particularly the miR-200/429 family and miR-155) in the epigenetic upregulation of GnRH transcription during the critical period (murine equivalent of the mini-puberty) [62]. Epigenetic changes during fetal life are also a potential mechanism for the effects of endocrine disrupting chemicals in utero [63].

Metabolism and Timing of Puberty

Nutritional changes play an important role in the observed secular trend towards an earlier age of pubertal onset in the developed world [64], as shown by the positive correlation between age at puberty onset and childhood body size, particularly in girls [65]. In contrast, undernutrition in females – for example, in chronic disease or anorexia nervosa – can result in delay in both the onset and the tempo of puberty [66].

This relationship between fat mass and pubertal timing is mediated, at least in part, through the permissive actions of the metabolic hormone leptin, a key regulator of body mass, produced from white adipose tissue [67]. Humans and mice lacking leptin (*Lep ob/ob*) or the leptin receptor (*LepR db/db*) fail to complete puberty and are infertile [68]. Genome-wide association studies of pubertal timing found, in addition to leptin signalling, overlap with several genes implicated in body mass index, including *FTO*, *SEC16B*, *TMEM18*, and *NEGR1* [18]. However, whilst self-limited DP in boys is associated with hypoleptinaemia [69], there have been no identified associations of specific leptin or leptin receptor polymorphisms with DP [70]. Ghrelin and other gut-derived peptides may also form part of the mechanism by which energy homeostasis regulates reproductive development [71]. Notably, children with constitutional delay of growth and puberty have a dual phenotype of slow growth in child-

Fig. 3. Schematic of the mechanism by which *IGSF10* mutations lead to delayed puberty. Reduced levels of *IGSF10* expression during embryogenesis in the corridor of the nasal mesenchyme from the vomeronasal organ (VNO) to the olfactory bulbs result in delayed migration of gonadotropin-releasing hormone (GnRH) neurons to the hypothalamus. This presents for the first time in adolescence as a phenotype of delayed puberty due to abnormalities of the GnRH neuronal network.

hood with DP. In contrast, both low birth weight and prematurity are associated with earlier onset of puberty [72], particularly in those children with a rapid increase in length or weight in the first 2 years of life [73]. It remains unclear, however, whether childhood obesity, insulin resistance, excess androgens, or underlying genetic or epigenetic factors may explain this association [74].

Recent Advances

Loss-of-function mutations in a member of the immunoglobulin superfamily, *IGSF1*, have been identified in patients with X-linked central hypothyroidism [75]. Notably, male patients with *IGSF1* mutations have a late increase in testosterone levels with a delayed pubertal growth spurt. However, pathogenic mutations in *IGSF1* have not been conclusively found in patients with isolated DP [76].

More recently, whole exome and targeted resequencing methods have implicated 2 pathogenic mutations in *IGSF10* as the causal factor for late puberty in 6 unrelated families from a large Finnish cohort with familial DP [77]. A further 2 rare variants of unknown significance were identified in 4 additional families from the cohort. Mutations in *IGSF10* appear to cause a dysregulation of GnRH neuronal migration during embryonic development (Fig. 3). An intact GnRH neurosecretory network is necessary for the correct temporal pacing of puberty.

Pathogenic *IGSF10* mutations leading to disrupted *IGSF10* signalling potentially result in reduced numbers or mistimed arrival of GnRH neurons at the hypothalamus, producing a functional defect in the GnRH neuroendocrine network. With this impaired GnRH system there would follow an increased “threshold” for the onset of puberty, with an ensuing delay in pubertal timing. *IGSF10* loss-of-function mutations were also discovered in patients with a hypothalamic amenorrhoea-like phenotype. These findings represent a new fetal origin of self-limited DP, and reveal a potential shared pathophysiology between DP and other forms of functional hypogonadism.

Conclusions

This review serves to highlight the fascinating heterogeneity of genetic defects resulting in delayed and disordered puberty. Although our understanding of the highly complex underlying biological network remains imperfect, results to date have demonstrated the importance of defects in GnRH neuronal development and function – GnRH receptor and LH/FSH abnormalities, transcriptional regulation of the HPG axis, and metabolic and energy homeostatic derangements – in the control of pubertal timing.

Clinically the distinction in adolescence between the conditions of DP and congenital idiopathic HH is an im-

portant but difficult one. Both disorders can present with a picture of functional hypogonadotropism and in some cases may share an underlying pathophysiology. There remains no definitive test to accurately discriminate between the two diagnoses. More complex and involved management is required in patients with hypogonadism to achieve both development of secondary sexual characteristics and to maximize the potential for fertility [78]. A rapid and efficient diagnosis of patients in the clinic

would represent a huge leap forward in patient care and a likely significant economic advantage. While presently next-generation sequencing in individuals presenting with delayed or incomplete pubertal development is only a reasonable option in a research setting, future progress in gene discovery and technical developments may facilitate the availability of genetic diagnosis as part of clinical care for patients with both GnRH deficiency and self-limiting DP.

References

- Cariboni A, Maggi R, Parnavelas JG: From nose to fertility: the long migratory journey of gonadotropin-releasing hormone neurons. *Trends Neurosci* 2007;30:638–644.
- Karges B, Neulen J, de Roux N, Karges W: Genetics of isolated hypogonadotropic hypogonadism: role of GnRH receptor and other genes. *Int J Endocrinol* 2012;2012:147893.
- de Muinich Keizer SM, Mul D: Trends in pubertal development in Europe. *Hum Reprod Update* 2001;7:287–291.
- Wehkalampi K, Widén E, Laine T, Palotie A, Dunkel L: Patterns of inheritance of constitutional delay of growth and puberty in families of adolescent girls and boys referred to specialist pediatric care. *J Clin Endocrinol Metab* 2008;93:723–728.
- Gajdos ZK, Hirschhorn JN, Palmert MR: What controls the timing of puberty? An update on progress from genetic investigation. *Curr Opin Endocrinol Diabetes Obes* 2009;16:16–24.
- Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP: The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. *Endocr Rev* 2003;24:668–693.
- Palmert MR, Dunkel L: Clinical practice. Delayed puberty. *N Engl J Med* 2012;366:443–453.
- Lawaetz JG, Hagen CP, Mieritz MG, Blomberg Jensen M, Petersen JH, Juul A: Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. *J Clin Endocrinol Metab* 2015;100:1376–1385.
- Zhu J, Chan YM: Adult consequences of self-limited delayed puberty. *Pediatrics* 2017;139:e20163177.
- Sedlmeyer IL, Palmert MR: Delayed puberty: analysis of a large case series from an academic center. *J Clin Endocrinol Metab* 2002;87:1613–1620.
- Sedlmeyer IL, Hirschhorn JN, Palmert MR: Pedigree analysis of constitutional delay of growth and maturation: determination of familial aggregation and inheritance patterns. *J Clin Endocrinol Metab* 2002;87:5581–5586.
- Ong KK, Elks CE, Li S, Zhao JH, Luan J, Andersson LB, et al: Genetic variation in *LIN28B* is associated with the timing of puberty. *Nat Genet* 2009;41:729–733.
- Perry JR, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, et al: Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature* 2014;514:92–97.
- Elks CE, Perry JR, Sulem P, Chasman DI, Franceschini N, He C, et al: Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nat Genet* 2010;42:1077–1085.
- Perry JR, Stolk L, Franceschini N, Lunetta KL, Zhai G, McArdle PF, et al: Meta-analysis of genome-wide association data identifies two loci influencing age at menarche. *Nat Genet* 2009;41:648–650.
- Tommiska J, Wehkalampi K, Vaaralahti K, Laitinen EM, Raivio T, Dunkel L: *LIN28B* in constitutional delay of growth and puberty. *J Clin Endocrinol Metab* 2010;95:3063–3066.
- Silveira-Neto AP, Leal LF, Emerman AB, Henderson KD, Piskounova E, Henderson BE, et al: Absence of functional *LIN28B* mutations in a large cohort of patients with idiopathic central precocious puberty. *Horm Res Paediatr* 2012;78:144–150.
- Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, Sulem P, et al: Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat Genet* 2017;49:834–841.
- Abreu AP, Dauber A, Macedo DB, Noel SD, Brito VN, Gill JC, et al: Central precocious puberty caused by mutations in the imprinted gene *MKRN3*. *N Engl J Med* 2013;368:2467–2475.
- Dauber A, Cunha-Silva M, Macedo DB, Brito VN, Abreu AP, Roberts SA, et al: Paternally inherited *DLK1* deletion associated with familial central precocious puberty. *J Clin Endocrinol Metab* 2017;102:1557–1567.
- Silveira LG, Noel SD, Silveira-Neto AP, Abreu AP, Brito VN, Santos MG, et al: Mutations of the *KISS1* gene in disorders of puberty. *J Clin Endocrinol Metab* 2010;95:2276–2280.
- Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, et al: A *GPR54*-activating mutation in a patient with central precocious puberty. *N Engl J Med* 2008;358:709–715.
- Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, et al: Reversal of idiopathic hypogonadotropic hypogonadism. *N Engl J Med* 2007;357:863–873.
- Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, et al: Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest* 2007;117:457–463.
- Chevrier L, Guimiot F, de Roux N: GnRH receptor mutations in isolated gonadotrophic deficiency. *Mol Cell Endocrinol* 2011;346:21–28.
- Lin L, Conway GS, Hill NR, Dattani MT, Hindmarsh PC, Achermann JC: A homozygous R262Q mutation in the gonadotropin-releasing hormone receptor presenting as constitutional delay of growth and puberty with subsequent borderline oligospermia. *J Clin Endocrinol Metab* 2006;91:5117–5121.
- Vaaralahti K, Wehkalampi K, Tommiska J, Laitinen EM, Dunkel L, Raivio T: The role of gene defects underlying isolated hypogonadotropic hypogonadism in patients with constitutional delay of growth and puberty. *Fertil Steril* 2011;95:2756–2758.
- Pugliese-Pires PN, Fortin JP, Arthur T, Latronico AC, Mendonca BB, Villares SM, et al: Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. *Eur J Endocrinol* 2011;165:233–241.
- Tornberg J, Sykiotis GP, Keefe K, Plummer L, Hoang X, Hall JE, et al: *Heparan sulfate 6-O-sulfotransferase 1*, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotropic hypogonadism. *Proc Natl Acad Sci USA* 2011;108:11524–11529.
- Pitteloud N, Meysing A, Quinton R, Acierno JS Jr, Dwyer AA, Plummer L, et al: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. *Mol Cell Endocrinol* 2006;254–255:60–69.

- 31 Xu C, Messina A, Somm E, Miraoui H, Kin-nunen T, Acierno JS Jr, et al: *KLB*, encoding β -Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism. *EMBO Mol Med* 2017;9:1379–1397.
- 32 Zhu J, Choa RE, Guo MH, Plummer L, Buck C, Palmert MR, et al: A shared genetic basis for self-limited delayed puberty and idiopathic hypogonadotropic hypogonadism. *J Clin Endocrinol Metab* 2015;100:E646–E654.
- 33 Kelberman D, Rizzoti K, Lovell-Badge R, Robinson IC, Dattani MT: Genetic regulation of pituitary gland development in human and mouse. *Endocr Rev* 2009;30:790–829.
- 34 Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP: Heritable disorders of pituitary development. *J Clin Endocrinol Metab* 1999;84:4362–4370.
- 35 Achermann JC, Gu WX, Kotlar TJ, Meeks JJ, Sabacan LP, Seminara SB, et al: Mutational analysis of *DAX1* in patients with hypogonadotropic hypogonadism or pubertal delay. *J Clin Endocrinol Metab* 1999;84:4497–4500.
- 36 Wolf NI, Vanderver A, van Spaendonk RM, Schiffmann R, Brais B, Bugiani M, et al; 4H Research Group: Clinical spectrum of 4H leukodystrophy caused by *POLR3A* and *POLR3B* mutations. *Neurology* 2014;83:1898–1905.
- 37 Margolin DH, Kousi M, Chan YM, Lim ET, Schmähmann JD, Hadjivassiliou M, et al: Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. *N Engl J Med* 2013;368:1992–2003.
- 38 Topaloglu AK, Lomniczi A, Kretschmar D, Dissen GA, Kotan LD, McArdle CA, et al: Loss-of-function mutations in *PNPLA6* encoding neuropathy target esterase underlie pubertal failure and neurological deficits in Gordon Holmes syndrome. *J Clin Endocrinol Metab* 2014;99:E2067–E2075.
- 39 Tata B, Huijbregts L, Jacquier S, Csaba Z, Genin E, Meyer V, et al: Haploinsufficiency of *Dmnl2*, encoding a synaptic protein, causes infertility associated with a loss of GnRH neurons in mouse. *PLoS Biol* 2014;12:e1001952.
- 40 Aligianis IA, Johnson CA, Gissen P, Chen D, Hampshire D, Hoffmann K, et al: Mutations of the catalytic subunit of *RAB3GAP* cause Warburg Micro syndrome. *Nat Genet* 2005;37:221–223.
- 41 Bem D, Yoshimura S, Nunes-Bastos R, Bond FC, Kurian MA, Rahman F, et al: Loss-of-function mutations in *RAB18* cause Warburg Micro syndrome. *Am J Hum Genet* 2011;88:499–507.
- 42 Themmen APN, Huhtaniemi IT: Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. *Endocr Rev* 2000;21:551–583.
- 43 Layman LC, Lee EJ, Peak DB, Namnoum AB, Vu KV, van Lingen BL, et al: Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone β -subunit gene. *N Engl J Med* 1997;337:607–611.
- 44 de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E: Hypogonadotropic hypogonadism due to loss of function of the *KISS1*-derived peptide receptor *GPR54*. *Proc Natl Acad Sci USA* 2003;100:10972–10976.
- 45 Seminara SB, Messenger S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al: The *GPR54* gene as a regulator of puberty. *N Engl J Med* 2003;349:1614–1627.
- 46 Topaloglu AK, Tello JA, Kotan LD, Ozbek MN, Yilmaz MB, Erdogan S, et al: Inactivating *KISS1* mutation and hypogonadotropic hypogonadism. *N Engl J Med* 2012;366:629–635.
- 47 Topaloglu AK, Reimann F, Guclu M, Yalin AS, Kotan LD, Porter KM, et al: *TAC3* and *TACR3* mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. *Nat Genet* 2009;41:354–358.
- 48 de Croft S, Boehm U, Herbison AE: Neurokinin B activates arcuate kisspeptin neurons through multiple tachykinin receptors in the male mouse. *Endocrinology* 2013;154:2750–2760.
- 49 Rance NE: Menopause and the human hypothalamus: evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. *Peptides* 2009;30:111–122.
- 50 Dungan HM, Clifton DK, Steiner RA: Mini-review: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. *Endocrinology* 2006;147:1154–1158.
- 51 Sandoval-Guzmán T, Rance NE: Central injection of senktide, an NK₃ receptor agonist, or neuropeptide Y inhibits LH secretion and induces different patterns of Fos expression in the rat hypothalamus. *Brain Res* 2004;1026:307–312.
- 52 Kung TT, Crawley Y, Jones H, Luo B, Gilchrist H, Greenfeder S, et al: Tachykinin NK₃-receptor deficiency does not inhibit pulmonary eosinophilia in allergic mice. *Pharmacol Res* 2004;50:611–615.
- 53 Tusset C, Noel SD, Trarbach EB, Silveira LF, Jorge AA, Brito VN, et al: Mutational analysis of *TAC3* and *TACR3* genes in patients with idiopathic central pubertal disorders. *Arq Bras Endocrinol Metabol* 2012;56:646–652.
- 54 Mitsushima D, Hei DL, Terasawa E: γ -Aminobutyric acid is an inhibitory neurotransmitter restricting the release of luteinizing hormone-releasing hormone before the onset of puberty. *Proc Natl Acad Sci USA* 1994;91:395–399.
- 55 Ojeda SR, Lomniczi A, Mastronardi C, Heger S, Roth C, Parent AS, et al: Minireview: the neuroendocrine regulation of puberty: is the time ripe for a systems biology approach? *Endocrinology* 2006;147:1166–1174.
- 56 Ducret E, Anderson GM, Herbison AE: RFamide-related peptide-3, a mammalian gonadotropin-inhibitory hormone ortholog, regulates gonadotropin-releasing hormone neuron firing in the mouse. *Endocrinology* 2009;150:2799–2804.
- 57 Ojeda SR, Lomniczi A, Sandau US: Glial-gonadotrophin hormone (GnRH) neurone interactions in the median eminence and the control of GnRH secretion. *J Neuroendocrinol* 2008;20:732–742.
- 58 Ojeda SR, Dubay C, Lomniczi A, Kaidar G, Matagne V, Sandau US, Dissen GA: Gene networks and the neuroendocrine regulation of puberty. *Mol Cell Endocrinol* 2010;324:3–11.
- 59 Ojeda SR, Hill J, Hill DF, Costa ME, Tapia V, Cornea A, Ma YJ: The Oct-2 POU domain gene in the neuroendocrine brain: a transcriptional regulator of mammalian puberty. *Endocrinology* 1999;140:3774–3789.
- 60 Lee BJ, Cho GJ, Norgren RB Jr, Junier MP, Hill DF, Tapia V, et al: TTF-1, a homeodomain gene required for diencephalic morphogenesis, is postnatally expressed in the neuroendocrine brain in a developmentally regulated and cell-specific fashion. *Mol Cell Neurosci* 2001;17:107–126.
- 61 Heger S, Mastronardi C, Dissen GA, Lomniczi A, Cabrera R, Roth CL, et al: Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis. *J Clin Invest* 2007;117:2145–2154.
- 62 Messina A, Langlet F, Chachlaki K, Roa J, Rasika S, Jouy N, et al: A microRNA switch regulates the rise in hypothalamic GnRH production before puberty. *Nat Neurosci* 2016;19:835–844.
- 63 Parent AS, Franssen D, Fudvoye J, Gérard A, Bourguignon JP: Developmental variations in environmental influences including endocrine disruptors on pubertal timing and neuroendocrine control: revision of human observations and mechanistic insight from rodents. *Front Neuroendocrinol* 2015;38:12–36.
- 64 Ong KK, Ahmed ML, Dunger DB: Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. *Mol Cell Endocrinol* 2006;254–255:8–12.
- 65 Biro FM, Khoury P, Morrison JA: Influence of obesity on timing of puberty. *Int J Androl* 2006;29:272–277; discussion 286–290.
- 66 Frisch RE, McArthur JW: Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. *Science* 1974;185:949–951.
- 67 Elias CF: Leptin action in pubertal development: recent advances and unanswered questions. *Trends Endocrinol Metab* 2012;23:9–15.
- 68 Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, et al: Leptin is a metabolic signal to the reproductive system. *Endocrinology* 1996;137:3144–3147.

- 69 Gill MS, Hall CM, Tillmann V, Clayton PE: Constitutional delay in growth and puberty (CDGP) is associated with hypoleptinaemia. *Clin Endocrinol (Oxf)* 1999;50:721–726.
- 70 Banerjee I, Trueman JA, Hall CM, Price DA, Patel L, Whatmore AJ, et al: Phenotypic variation in constitutional delay of growth and puberty: relationship to specific leptin and leptin receptor gene polymorphisms. *Eur J Endocrinol* 2006;155:121–126.
- 71 Pomerants T, Tillmann V, Karelson K, Jürimäe J, Jürimäe T: Ghrelin response to acute aerobic exercise in boys at different stages of puberty. *Horm Metab Res* 2006;38:752–757.
- 72 Persson I, Ahlsson F, Ewald U, Tuvemo T, Qingyuan M, von Rosen D, Proos L: Influence of perinatal factors on the onset of puberty in boys and girls: implications for interpretation of link with risk of long term diseases. *Am J Epidemiol* 1999;150:747–755.
- 73 Wehkalampi K, Hovi P, Dunkel L, Strang-Karlsson S, Järvenpää AL, Eriksson JG, et al: Advanced pubertal growth spurt in subjects born preterm: the Helsinki Study of Very Low Birth Weight Adults. *J Clin Endocrinol Metab* 2011;96:525–533.
- 74 Dunger DB, Ahmed ML, Ong KK: Early and late weight gain and the timing of puberty. *Mol Cell Endocrinol* 2006;254–255:140–145.
- 75 Sun Y, Bak B, Schoenmakers N, van Trotsenburg AS, Oostdijk W, Voshol P, et al: Loss-of-function mutations in *IGSF1* cause an X-linked syndrome of central hypothyroidism and testicular enlargement. *Nat Genet* 2012;44:1375–1381.
- 76 Joustra SD, Wehkalampi K, Oostdijk W, Biermasz NR, Howard S, Silander TL, et al: *IGSF1* variants in boys with familial delayed puberty. *Eur J Pediatr* 2015;174:687–692.
- 77 Howard SR, Guasti L, Ruiz-Babot G, Mancini A, David A, Storr HL, et al: *IGSF10* mutations dysregulate gonadotropin-releasing hormone neuronal migration resulting in delayed puberty. *EMBO Mol Med* 2016;8:626–642.
- 78 Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, et al: Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism – pathogenesis, diagnosis and treatment. *Nat Rev Endocrinol* 2015;11:547–564.